483
Protein Sciences CorporationProtein Sciences Corporation – FDA 483, May 2, 2024
Record Details
An FDA inspection of Protein Sciences Corporation in Pearl River, NY, revealed significant deficiencies in their manufacturing and quality control processes for Flublok drug products. Key issues included inadequate laboratory controls, failure to properly investigate deviations and out-of-specification results, and poor environmental monitoring and facility maintenance. These findings indicate a lack of robust quality systems impacting product quality and safety.
View Company Profile
ID · 99eff266-6766-4cf2-81af-eb0aace5280e
Other documents for Protein Sciences Corporation
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.